EZH2 and head and neck squamous cell carcinoma: At the same time, the authors demonstrated that both pharmacologic inhibition and genetically reduced EZH2 expression resulted in a better antigen presentation by inducing a high MHC-I expression in a preclinical model of HNSCC [147].